Logo image of INDP

INDAPTUS THERAPEUTICS INC (INDP) Stock Fundamental Analysis

NASDAQ:INDP - Nasdaq - US45339J1051 - Common Stock - Currency: USD

0.338  -0.06 (-15.5%)

After market: 0.3454 +0.01 (+2.19%)

Fundamental Rating

2

INDP gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. The financial health of INDP is average, but there are quite some concerns on its profitability. INDP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

INDP had negative earnings in the past year.
INDP had a negative operating cash flow in the past year.
INDP had negative earnings in each of the past 5 years.
INDP had a negative operating cash flow in each of the past 5 years.
INDP Yearly Net Income VS EBIT VS OCF VS FCFINDP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

INDP has a worse Return On Assets (-291.00%) than 93.57% of its industry peers.
INDP has a Return On Equity of -562.48%. This is in the lower half of the industry: INDP underperforms 79.29% of its industry peers.
Industry RankSector Rank
ROA -291%
ROE -562.48%
ROIC N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
INDP Yearly ROA, ROE, ROICINDP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INDP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INDP Yearly Profit, Operating, Gross MarginsINDP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for INDP has been increased compared to 1 year ago.
Compared to 5 years ago, INDP has more shares outstanding
There is no outstanding debt for INDP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INDP Yearly Shares OutstandingINDP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
INDP Yearly Total Debt VS Total AssetsINDP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -24.80, we must say that INDP is in the distress zone and has some risk of bankruptcy.
INDP has a worse Altman-Z score (-24.80) than 87.50% of its industry peers.
INDP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -24.8
ROIC/WACCN/A
WACCN/A
INDP Yearly LT Debt VS Equity VS FCFINDP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.90 indicates that INDP should not have too much problems paying its short term obligations.
INDP's Current ratio of 1.90 is on the low side compared to the rest of the industry. INDP is outperformed by 77.50% of its industry peers.
A Quick Ratio of 1.90 indicates that INDP should not have too much problems paying its short term obligations.
The Quick ratio of INDP (1.90) is worse than 76.43% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
INDP Yearly Current Assets VS Current LiabilitesINDP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

INDP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.76%, which is quite good.
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, INDP will show a very strong growth in Earnings Per Share. The EPS will grow by 33.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.26%
EPS Next 2Y26.62%
EPS Next 3Y17.04%
EPS Next 5Y33.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INDP Yearly Revenue VS EstimatesINDP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2028 2029 2030 2031 2032 100M 200M 300M 400M
INDP Yearly EPS VS EstimatesINDP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INDP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INDP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INDP Price Earnings VS Forward Price EarningsINDP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INDP Per share dataINDP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

INDP's earnings are expected to grow with 17.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.62%
EPS Next 3Y17.04%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INDP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INDAPTUS THERAPEUTICS INC

NASDAQ:INDP (5/30/2025, 8:05:11 PM)

After market: 0.3454 +0.01 (+2.19%)

0.338

-0.06 (-15.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)N/A N/A
Inst Owners4.52%
Inst Owner Change7.64%
Ins Owners35.34%
Ins Owner Change0%
Market Cap5.42M
Analysts82.5
Price Target8.67 (2465.09%)
Short Float %1.29%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-29.48%
Min EPS beat(2)-74.29%
Max EPS beat(2)15.33%
EPS beat(4)3
Avg EPS beat(4)-2.76%
Min EPS beat(4)-74.29%
Max EPS beat(4)33.25%
EPS beat(8)7
Avg EPS beat(8)9.34%
EPS beat(12)11
Avg EPS beat(12)11.28%
EPS beat(16)13
Avg EPS beat(16)6.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)30.91%
EPS NQ rev (3m)30.91%
EPS NY rev (1m)0%
EPS NY rev (3m)27.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-1.49
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.84
OCFYN/A
SpS0
BVpS0.17
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -291%
ROE -562.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.69%
ROA(5y)-89.14%
ROE(3y)-188.88%
ROE(5y)-137.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -24.8
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.89%
EPS Next Y50.26%
EPS Next 2Y26.62%
EPS Next 3Y17.04%
EPS Next 5Y33.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.96%
OCF growth 3YN/A
OCF growth 5YN/A